Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali
Background. Yellow fever (YF) is still a major public health problem in endemic regions of Africa and South America. In Africa, one of the main control strategies is routine vaccination within the Expanded Programme on Immunization (EPI). A new meningococcal A conjugate vaccine (PsA-TT) is about to...
Main Authors: | Roy Chowdhury, Panchali, Meier, Christian, Laraway, Hewad, Tang, Yuxiao, Hodgson, Abraham, Sow, Samba O., Enwere, Godwin C., Plikaytis, Brian D., Kulkarni, Prasad S., Preziosi, Marie-Pierre, Niedrig, Matthias |
---|---|
Format: | Online |
Language: | English |
Published: |
Oxford University Press
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639505/ |
Similar Items
-
Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac
by: Tang, Yuxiao, et al.
Published: (2015) -
MenAfriVac as an Antitetanus Vaccine
by: Borrow, Ray, et al.
Published: (2015) -
A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians
by: Tapia, Milagritos D., et al.
Published: (2015) -
Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials
by: Idoko, Olubukola T., et al.
Published: (2015) -
Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age
by: Tapia, Milagritos D., et al.
Published: (2015)